TY - JOUR
T1 - Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
AU - Kakihana, Kazuhiko
AU - Fujioka, Yuki
AU - Suda, Wataru
AU - Najima, Yuho
AU - Kuwata, Go
AU - Sasajima, Satoshi
AU - Mimura, Iyo
AU - Morita, Hidetoshi
AU - Sugiyama, Daisuke
AU - Nishikawa, Hiroyoshi
AU - Hattori, Masahira
AU - Hino, Yutaro
AU - Ikegawa, Shuntaro
AU - Yamamoto, Keita
AU - Toya, Takashi
AU - Doki, Noriko
AU - Koizumi, Koichi
AU - Honda, Kenya
AU - Ohashi, Kazuteru
N1 - Funding Information:
The authors are very grateful to the patients and FMT donors who participated in this study. The authors thank Noritaka Sekiya for his professional advice regarding antibiotic use and donor screening. This work was supported by Grants-in-Aid for Scientific Research (B) (no. 26290054) (H.N.) and for challenging Exploratory Research (no. 16K15551) (H.N.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by The National Cancer Center Research and Development Fund (no. 28-A-7) (H.N.).
Publisher Copyright:
© 2016 by The American Society of Hematology.
PY - 2016/10/20
Y1 - 2016/10/20
N2 - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.
AB - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.
UR - http://www.scopus.com/inward/record.url?scp=84992074418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992074418&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-05-717652
DO - 10.1182/blood-2016-05-717652
M3 - Review article
C2 - 27461930
AN - SCOPUS:84992074418
SN - 0006-4971
VL - 128
SP - 2083
EP - 2088
JO - Blood
JF - Blood
IS - 16
ER -